Literature DB >> 15969349

[Genomic instability associated with human LINE-1 rétrotransposition].

Nicolas Gilbert1, Aurélien J Doucet, Alain Bucheton.   

Abstract

LINE-1 (L1) retrotransposon accounts for approximately 17 % of the human genome. Because of the great number of identical copies, L1 can be implicated in genomic rearrangements associated with events of homologous recombination between heterologous sites. Moreover, even if the vast majority of the L1 elements are inactive, some are still able to mobilize themselves by retrotransposition. Thus, L1 is regarded as an insertional mutagenic agent. Moreover, recent works have shown that active retrotransposons were able to mobilize other sequences to generate retro-pseudogenes or to amplify other repeated sequences. Finally, L1 has been associated recently with new genomic rearrangements generated upon insertions such as large genomic deletions. L1 then can be considered as a major factor that has affected and shaped the human genome through several mechanisms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15969349

Source DB:  PubMed          Journal:  J Soc Biol        ISSN: 1295-0661


  3 in total

1.  Differential LINE-1 Hypomethylation of Gastric Low-Grade Dysplasia from High Grade Dysplasia and Intramucosal Cancer.

Authors:  Jeong Rok Lee; Woo Chul Chung; Jin Dong Kim; Kang Moon Lee; Chang Nyol Paik; Sung Hoon Jung; Ji Han Jung; Yun Kyung Lee; Sok Won Han
Journal:  Gut Liver       Date:  2011-06-24       Impact factor: 4.519

2.  Association between Genetic Instability and Helicobacter pylori Infection in Gastric Epithelial Dysplasia.

Authors:  Jin Su Kim; Woo Chul Chung; Kang-Moon Lee; Chang Nyol Paik; Kyeong Soo Lee; Hye Ji Kim; Young Wook Kim; Ji Han Jung; Seung June Noh; Yun Kyung Lee
Journal:  Gastroenterol Res Pract       Date:  2012-12-30       Impact factor: 2.260

Review 3.  Mutagenesis in rodents using the L1 retrotransposon.

Authors:  Eric M Ostertag; Blair B Madison; Hiroki Kano
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.